Skip to main content
Top
Published in: Drugs & Aging 1/2020

01-01-2020 | Original Research Article

Frequency and Predictors of Polypharmacy in US Medicare Patients: A Cross-Sectional Analysis at the Patient and Physician Levels

Authors: Michael I. Ellenbogen, Peiqi Wang, Heidi N. Overton, Christine Fahim, Angela Park, William E. Bruhn, Jennifer L. Carnahan, Amy M. Linsky, Seki A. Balogun, Martin A. Makary

Published in: Drugs & Aging | Issue 1/2020

Login to get access

Abstract

Background

Polypharmacy in older patients increases the risk of medication-related adverse events and can be a marker of unnecessary care.

Objectives

The aim of this study was to describe the frequency of polypharmacy among patients 65 years of age or older and identify factors associated with the occurrence of patient-level and physician-level polypharmacy.

Methods

We performed a cross-sectional analysis of 100% Medicare claims data from January 1, 2016 to December 31, 2016. All patients with continuous Medicare coverage (Parts A, B, and D) throughout 2016 who were 65 years of age or older and who were prescribed at least one medication for at least 30 days were included in the analysis. Each patient was attributed to the primary care physician who prescribed them the most medications. Physicians treating fewer than ten patients were excluded. We defined polypharmacy based on the highest number of concurrent medications at any point during the year. We used hierarchical linear regression to study patient- and physician-level characteristics associated with high prescribing rates.

Results

We identified 25,747,560 patients attributed to 147,879 primary care physicians. The patient-level mean [standard deviation (SD)] concurrent medication rate was 5.6 (3.3), and the physician-level mean (SD) was 5.6 (1.1). A total of 6108 physicians (4.1% of sample) had a mean concurrent number of medications greater than two SDs above the physician-level mean. At the patient level in the adjusted model, a history of HIV/AIDS, diabetes mellitus, solid organ transplant, and systolic heart failure were the comorbidities most strongly associated with polypharmacy. The relative difference in number of medications associated with these comorbidities were 1.89, 1.39, 1.32, and 1.06, respectively. At the physician level, increased time since medical school graduation and smaller practice size were associated with lower rates of polypharmacy.

Conclusions

Patterns of high prescribing to older patients is common and measurable at the physician level. Addressing high outlier prescribers may represent an opportunity to reduce avoidable harm and excessive costs.
Literature
2.
go back to reference Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol Ser A Biol Sci Med Sci. 2015;70(8):989–95.CrossRef Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol Ser A Biol Sci Med Sci. 2015;70(8):989–95.CrossRef
3.
go back to reference Wu TY, Chie WC, Yang RS, Liu JP, Kuo KL, Wong WK, et al. Factors associated with falls among community-dwelling older people in Taiwan. Ann Acad Med Singapore. 2013;42(7):320–7.PubMed Wu TY, Chie WC, Yang RS, Liu JP, Kuo KL, Wong WK, et al. Factors associated with falls among community-dwelling older people in Taiwan. Ann Acad Med Singapore. 2013;42(7):320–7.PubMed
4.
go back to reference Lai S, Liao K, Liao C, Muo C, Liu C, Sung F. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine. 2010;89(5):295–9.CrossRef Lai S, Liao K, Liao C, Muo C, Liu C, Sung F. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine. 2010;89(5):295–9.CrossRef
5.
go back to reference Jensen GL, Friedmann JM, Coleman CD, Smiciklas-Wright H. Screening for hospitalization and nutritional risks among community-dwelling older persons. Am J Clin Nutr. 2001;74(2):201–5.CrossRef Jensen GL, Friedmann JM, Coleman CD, Smiciklas-Wright H. Screening for hospitalization and nutritional risks among community-dwelling older persons. Am J Clin Nutr. 2001;74(2):201–5.CrossRef
6.
go back to reference Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547–60.CrossRef Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547–60.CrossRef
7.
go back to reference Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.CrossRef Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.CrossRef
9.
go back to reference Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858.CrossRef Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858.CrossRef
12.
go back to reference Xue Y, Goodwin JS, Adhikari D, Raji MA, Kuo Y-F. Trends in primary care provision to medicare beneficiaries by physicians, nurse practitioners, or physician assistants: 2008-2014. J Primary Care Community Health. 2017;8(4):256–63.CrossRef Xue Y, Goodwin JS, Adhikari D, Raji MA, Kuo Y-F. Trends in primary care provision to medicare beneficiaries by physicians, nurse practitioners, or physician assistants: 2008-2014. J Primary Care Community Health. 2017;8(4):256–63.CrossRef
13.
go back to reference Chan DC, Hao YT, Wu SC. Polypharmacy among disabled taiwanese elderly: a longitudinal observational study. Drugs Aging. 2009;26(4):345–54.CrossRef Chan DC, Hao YT, Wu SC. Polypharmacy among disabled taiwanese elderly: a longitudinal observational study. Drugs Aging. 2009;26(4):345–54.CrossRef
14.
go back to reference Fincke BG, Snyder K, Cantillon C, Gaehde S, Standring P, Fiore L, et al. Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Saf. 2005;14(2):121–8.CrossRef Fincke BG, Snyder K, Cantillon C, Gaehde S, Standring P, Fiore L, et al. Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Saf. 2005;14(2):121–8.CrossRef
15.
go back to reference Sato I, Akazawa M. Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study. Drug Healthc Patient Saf. 2013;24(5):143–50. Sato I, Akazawa M. Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study. Drug Healthc Patient Saf. 2013;24(5):143–50.
18.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRef Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRef
19.
go back to reference Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRef Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRef
20.
go back to reference van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–33.CrossRef van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–33.CrossRef
21.
go back to reference Mehta HB, Sura SD, Adhikari D, Andersen CR, Williams SB, Senagore AJ, et al. Adapting the Elixhauser comorbidity index for cancer patients: comparison of comorbidity scores in surgery. Cancer. 2018;124(9):2018–25.CrossRef Mehta HB, Sura SD, Adhikari D, Andersen CR, Williams SB, Senagore AJ, et al. Adapting the Elixhauser comorbidity index for cancer patients: comparison of comorbidity scores in surgery. Cancer. 2018;124(9):2018–25.CrossRef
22.
go back to reference Neuman P, Jacobson GA. Medicare Advantage Checkup. N Engl J Med. 2018;379(22):2163–72.CrossRef Neuman P, Jacobson GA. Medicare Advantage Checkup. N Engl J Med. 2018;379(22):2163–72.CrossRef
25.
go back to reference Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75 + Study: a cross-sectional analysis. Drugs Aging. 2009;26(6):493–503.CrossRef Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75 + Study: a cross-sectional analysis. Drugs Aging. 2009;26(6):493–503.CrossRef
26.
go back to reference Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2006;24(1):14–9.CrossRef Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2006;24(1):14–9.CrossRef
27.
go back to reference Gupta N, Hu B, Kim L, Lam S, Russo-Alvarez G, Rothberg M. Physician level polypharmacy variation-society of general internal medicine abstract presentation. 2019. Washington DC. Gupta N, Hu B, Kim L, Lam S, Russo-Alvarez G, Rothberg M. Physician level polypharmacy variation-society of general internal medicine abstract presentation. 2019. Washington DC.
28.
go back to reference Qato DM, Alexander GC, Conti RM, Qato DM, Johnson M, Schumm P, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA J Am Med Assoc. 2008;300(24):2867–78.CrossRef Qato DM, Alexander GC, Conti RM, Qato DM, Johnson M, Schumm P, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA J Am Med Assoc. 2008;300(24):2867–78.CrossRef
29.
go back to reference Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24.CrossRef Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24.CrossRef
30.
go back to reference Mangin D, Bahat G, Golomb BA, Mallery LH, Moorhouse P, Onder G, et al. International group for reducing inappropriate medication use & polypharmacy (IGRIMUP): position statement and 10 recommendations for action. Drugs Aging. 2018;35(7):575–87.CrossRef Mangin D, Bahat G, Golomb BA, Mallery LH, Moorhouse P, Onder G, et al. International group for reducing inappropriate medication use & polypharmacy (IGRIMUP): position statement and 10 recommendations for action. Drugs Aging. 2018;35(7):575–87.CrossRef
31.
go back to reference Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827.CrossRef Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827.CrossRef
32.
go back to reference Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRef Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRef
33.
go back to reference Makary MA, Mehta A, Xu T. Improving wisely using physician metrics. Am J Med Qual. 2018;33(1):103–5.CrossRef Makary MA, Mehta A, Xu T. Improving wisely using physician metrics. Am J Med Qual. 2018;33(1):103–5.CrossRef
34.
go back to reference Sirovich BE. Too little? Too much? Primary care physicians’ views on US Health Care: a brief report. Arch Intern Med. 2011;171(17):1582.CrossRef Sirovich BE. Too little? Too much? Primary care physicians’ views on US Health Care: a brief report. Arch Intern Med. 2011;171(17):1582.CrossRef
35.
go back to reference Sacarny A, Barnett ML, Le J, Tetkoski F, Yokum D, Agrawal S. Effect of peer comparison letters for high-volume primary care prescribers of quetiapine in older and disabled adults: a randomized clinical trial. JAMA Psychiatry. 2018;75(10):1003.CrossRef Sacarny A, Barnett ML, Le J, Tetkoski F, Yokum D, Agrawal S. Effect of peer comparison letters for high-volume primary care prescribers of quetiapine in older and disabled adults: a randomized clinical trial. JAMA Psychiatry. 2018;75(10):1003.CrossRef
Metadata
Title
Frequency and Predictors of Polypharmacy in US Medicare Patients: A Cross-Sectional Analysis at the Patient and Physician Levels
Authors
Michael I. Ellenbogen
Peiqi Wang
Heidi N. Overton
Christine Fahim
Angela Park
William E. Bruhn
Jennifer L. Carnahan
Amy M. Linsky
Seki A. Balogun
Martin A. Makary
Publication date
01-01-2020
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 1/2020
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00726-0

Other articles of this Issue 1/2020

Drugs & Aging 1/2020 Go to the issue